Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer

Research output: Contribution to journal › Meeting abstract › Contributed › peer-review

Contributors

  • T. Trarbach - , TUD Dresden University of Technology (Author)
  • K. Schuette - , University Palliative Centre (UPC) (Author)
  • J. Stoehlmacher - , TUD Dresden University of Technology (Author)
  • E. Goekkurt - , TUD Dresden University of Technology (Author)
  • H. Guenther - , TUD Dresden University of Technology (Author)
  • U. Ubbelohde - , Department of internal Medicine I, TUD Dresden University of Technology (Author)
  • C. Stroszczynski - , TUD Dresden University of Technology (Author)
  • G. Ehninger - , TUD Dresden University of Technology (Author)
  • G. Folprecht - , Department of internal Medicine I, TUD Dresden University of Technology (Author)

Details

Original languageEnglish
Article numbere15025
Number of pages2
JournalJournal of clinical oncology
Volume27
Issue number15
Publication statusPublished - 20 May 2009
Peer-reviewedYes

Conference

Title45th Annual Meeting of the American-Society-of-Clinical-Oncology
Duration29 May - 2 June 2009
CityOrlando
CountryUnited States of America

External IDs

ORCID /0000-0002-9321-9911/work/142252007

Keywords

Sustainable Development Goals